MicroTransponder, Inc., a privately-held medical device company, has
just announced a $7 Million Series B round of funding. MicroTransponder
is developing a wireless neurostimulation platform for the treatment of
chronic pain and other neurological indications.
“The
support from the NINDS has been essential to the bringing this
technology closer to regulatory clearance”
In addition, the Company is announcing that it has been awarded a $2.6
Million NINDS SBIR FastTrack U44 grant, which is a milestone-driven
cooperative agreement to support pre-clinical validation of devices for
the treatment of neuropathic pain and manufacturing scale-up. “The
support from the NINDS has been essential to the bringing this
technology closer to regulatory clearance,” stated CEO Will Rosellini.
This funding has allowed the Company to hire premier clinical and
regulatory expertise and to prepare a series of clinical trials and
regulatory filings on their initial product, the SAINT™ System for
chronic pain. “We continue to focus on hiring the top neurostimulation
talent,” stated CEO Rosellini. “Dr. Evan Rosenfeld has extensive
clinical and regulatory expertise in the field of neurostimulation and
chronic pain. Brent Tarver was part of the initial core team that
brought neurostimulation therapy for the treatment of epilepsy from
concept to bedside. Both individuals will drive our aggressive clinical
and regulatory program to demonstrate the clinical utility of wireless
neurostimulation,” continued Rosellini. The Series B round of funding
consisted of existing Series A investors and new angel investors.
New Additions to Management